Geranylgeraniol – A new potential therapeutic approach to bisphosphonate associated osteonecrosis of the jaw

Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation <i>in vitro</i>

John Fisher, Michael J. Rogers, J. M. Halasy et al. · Proceedings of the National Academy of Sciences · 1999 · 679 citations

Sclerostin, Bone Resorption, Macrophage Apoptosis +17

Farnesol and Geranylgeraniol Prevent Activation of Caspases by Aminobisphosphonates: Biochemical Evidence for Two Distinct Pharmacological Classes of Bisphosphonate Drugs

Helena L. Benford, Julie C. Frith, Seppo Auriola et al. · Molecular Pharmacology · 1999 · 256 citations

The Role of Geranylgeranylation in Bone Resorption and Its Suppression by Bisphosphonates in Fetal Bone Explants In Vitro: A Clue to the Mechanism of Action of Nitrogen-Containing Bisphosphonates

Ermond van Beek, Clemens W.G.M. Löwik, Gabri van der Pluijm et al. · Journal of Bone and Mineral Research · 1999 · 240 citations

The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway.

C M Shipman, Peter I. Croucher, R.G.G. Russell et al. · PubMed · 1998 · 220 citations

Chemoprevention Strategy, Apoptosis, Immunology +16

“Bis-phossy jaws” – High and low risk factors for bisphosphonate-induced osteonecrosis of the jaw

Mario Hakim Abu-Id, Patrick H. Warnke, Joachim Gottschalk et al. · Journal of Cranio-Maxillofacial Surgery · 2008 · 217 citations

Bone Disease, Bone Health, Oral Biology +7